Chromium is a transition element occurring in the environment (soil, rocks, plants, dust, and gases), primarily in the elemental, trivalent \[Cr(III)\], and hexavalent \[Cr(VI)\] oxidation states. Both Cr(III) and Cr(VI) are environmentally stable, and their toxicologic profiles are well known; Cr(III) has limited toxicologic properties \[[@b11-ehp0114-000542]; [@b21-ehp0114-000542]\] and is considered to be an essential trace metal in humans ([@b3-ehp0114-000542]), whereas various Cr(VI) compounds are considered to be human carcinogens \[[@b5-ehp0114-000542]; [@b10-ehp0114-000542]; [@b13-ehp0114-000542]; [@b21-ehp0114-000542]; [@b22-ehp0114-000542]; [@b30-ehp0114-000542]\], are known to induce both acute and chronic toxic effects ([@b5-ehp0114-000542]), and are of the greatest occupational and environmental health concern.

The respiratory tract is the main target organ of Cr(VI) toxicity associated with both acute (short-term) and chronic (long-term) inhalation ([@b5-ehp0114-000542]; [@b10-ehp0114-000542]): acute exposure may cause shortness of breath, coughing, and wheezing ([@b32-ehp0114-000542]). Chronic exposure leads to ulcerations and perforations of the nasal septum, chronic bronchitis, decreased pulmonary function, pneumonia, and other respiratory effects ([@b7-ehp0114-000542]). On the basis of experimental and epidemiologic evidence ([@b10-ehp0114-000542]; [@b18-ehp0114-000542]; [@b24-ehp0114-000542]; [@b31-ehp0114-000542]), IARC has classified Cr(VI) as a class 1 carcinogen (recognized human carcinogen).

Cr(VI) compounds are used in several industrial applications (chrome plating, welding inox steel and other special steels, painting, leather tanning, and wood preserving). Occupational exposure mainly occurs by inhalation, but it may involve the gastrointestinal tract and skin ([@b10-ehp0114-000542]). Therefore, the respiratory tract is the primary target organ for Cr(VI) compounds. Experimental work on the rat showed that lung accumulation of Cr(VI) can be observed even after intravenous administration ([@b25-ehp0114-000542]). The mechanism of Cr(VI) cytotoxicity is not completely understood, but several studies have shown that Cr(VI) compounds induce oxidative stress, DNA damage, apoptotic cell death, and altered gene expression ([@b6-ehp0114-000542]; [@b36-ehp0114-000542]; [@b38-ehp0114-000542]). The reduction in Cr(VI) levels induced by redox-active enzymes and small molecules generates intermediate unstable states, such as Cr(V) or Cr(IV), that may mediate the formation of free hydroxyl, thiyl, ascorbate, and carbon-based radicals ([@b13-ehp0114-000542]; [@b23-ehp0114-000542]; [@b30-ehp0114-000542]) that are capable of damaging macromolecular targets, such as DNA ([@b34-ehp0114-000542]). Interestingly, although Cr(III) reacts with DNA and proteins, it is unable to cross cell membranes. The opposite occurs for Cr(VI) species, which do not react with nucleophilic targets but can easily cross cell membrane through anion channels. Once inside the cell, Cr(VI) is rapidly reduced to the trivalent state, and Cr(III) then interacts with cell proteins and DNA ([@b23-ehp0114-000542]).

Improved work areas, procedures, and hygiene measures have minimized occupational exposure to Cr(VI) compounds and led to a reduction in traditional adverse effects on the lung, such as tracheobronchitis or pneumonia; however, long-term Cr(VI) exposure may still cause airway disorders, including airway irritation, sensitization, and lung cancer. Sensitive tests are therefore needed to evaluate early biochemical changes that occur in the respiratory tract after Cr(VI) exposure. Furthermore, because the respiratory tract is the primary route of exposure to Cr(VI), the quantification of biomarkers of free radical production at the target organ level could improve the sensitivity and specificity of putative biomarkers.

We have recently shown that exhaled breath condensate (EBC), a fluid formed as a result of the cooling of expired air, is a suitable matrix not only for assessing the biomarkers of oxidative stress in exposed workers \[malondialdehyde (MDA)\] but also for quantifying the levels of some pneumotoxic substances in the lung, in particular, cobalt ([@b20-ehp0114-000542]). The synergistic effect of tungsten to power the lipid peroxidation caused by cobalt has also been demonstrated ([@b20-ehp0114-000542]).

The aim of the present study was to investigate Cr levels in the EBC of workers employed in the chrome-plating industry and to assess early biochemical changes in the airways by analyzing EBC biomarkers of oxidative stress, such as hydrogen peroxide (H~2~O~2~) and MDA.

Materials and Methods
=====================

Subjects.
---------

[Table 1](#t1-ehp0114-000542){ref-type="table"} shows the demographic and clinical characteristics of the 24 chrome-plating workers recruited in the study, each of whom carried out various tasks during the same work day. Four of these subjects have a history of light smoking status (\< 10 cigarettes/day, corresponding to \< 10 packs/year), but we did not find any differences in exhaled biomarker levels between smoking and nonsmoking workers. All of the workforce volunteered to participate in this study, which took place during paid work hours. The "healthy worker effect" cannot be ruled out, owing to preemployment selection procedures. However, all of these workers underwent medical health surveillance, and all were asymptomatic and presumably healthy. The control group consisted of 25 healthy adult volunteers with no significant history of lung disease and who were not occupationally exposed to Cr. The workers also exhibited normal spirometric indices and did not report any significant previous or current respiratory diseases. None of them had any symptoms of acute respiratory illness during the 4 weeks preceding the study. We found no differences between male and female control subjects for the studied biomarkers.

Study design.
-------------

Before enrollment, the subjects completed a short questionnaire concerning their current and previous medical history and underwent a spirometric examination. The EBC and urine samples of the workers were assessed three times: *a*) before the work shift on Friday (*T*~0~); *b*) at the end of the same shift, after 8 hr of work (*T*~1~); and *c*) before exposure on the following Monday (*T*~2~). EBC and urine samples from the controls were collected in our laboratory during a normal work day, and a subgroup of 10 subjects repeated the procedures in the office area of the work-place in order to exclude any contamination by the office environmental air.

All of the subjects gave their written informed consent to the procedures, which were approved by our local ethics committee. The biologic material was sampled as described in the Declaration of Helsinki ([@b37-ehp0114-000542]).

Spirometric measurements.
-------------------------

Spirometry was performed using a pneumotachograph (Koko Spirometer, Sensormedics, Milan, Italy). Mean forced expiratory volume in 1 sec (FEV~1~) and forced vital capacity (FVC) were obtained from the three best acceptable test values of lung function, as recommended by the [@b2-ehp0114-000542].

Environmental measurements.
---------------------------

Ambient monitoring was carried out by personal samplers. Briefly, airborne particulate was collected on polyvinyl chloride membrane filters (5.0 μm porosity, 25 mm diameter) according to National Institute of Occupational Safety and Health (NIOSH) protocol 7300 ([@b28-ehp0114-000542]) at a constant flow of 3 L/min for a period ranging from 90 to 150 min in the morning or afternoon of the Friday work shift. The membranes were weighed in a thermo-hygrometrically conditioned cabinet using a precision balance with a sensitivity of 0.01 mg and dissolved in concentrated hyperpure nitric acid (70%), and the solution was diluted with ultrapure water. The analytical blank was obtained from virgin membranes. Total Cr was analyzed by means of electrothermal atomic absorption spectroscopy (ETAAS) with Zeeman background correction following UNICHIM (Italian Association for Unification in the Sector of Chemical Industry) method 886 ([@b35-ehp0114-000542]), and expressed as micrograms per cubic meter. To validate the precision and the sensitivity of our method, we used the standard addition method using a certified Cr(VI) standard solution (Fluka, Milan, Italy). The amount of soluble hexavalent Cr in the ambient air was estimated following NIOSH protocol 7703 ([@b29-ehp0114-000542]) after air collection using stationary samplers in the work rooms and office of the plant.

Airborne concentrations of total Cr for the Friday work shift were 8.8 (2.6) μg/m^3^ \[GM (GSD)\] in the morning and 5.0 (2.5) μg/m^3^ in the afternoon, and the weighted average was 7.8 (2.3) μg/m^3^. Workers were significantly more exposed in the morning (*p* \< 0.05) than during the afternoon half-shift, whereas there were no significant differences in the collection times between morning and afternoon. Soluble Cr(VI) was about 70% of the total Cr monitored in the environment (data not shown); therefore, all measured Cr samples were below the limit proposed by the American Conference of Governmental Industrial Hygienists ([@b1-ehp0114-000542]) for water-soluble Cr(VI) organic compounds (50 μg/m^3^).

EBC collection.
---------------

EBC was collected using a new portable TURBO-DECCS condenser (transportable unit for research on biomarkers obtained from disposable exhaled condensate collection systems; ItalChill, Parma, Italy; [Figure 1A](#f1-ehp0114-000542){ref-type="fig"}) specifically designed to collect EBC in clinical and work settings. The condenser has a refrigerating system (TURBO) that thermostatically controls the working temperature, and a disposable respiratory system (DECCS) that consists of a mouthpiece connected to a one-way aspiration valve and (through a tube with a special stopper) an EBC collection test tube at the end ([Figure 1B](#f1-ehp0114-000542){ref-type="fig"}). On the basis of preliminary data (not shown), we chose a condensation temperature of --5°C ([@b19-ehp0114-000542]), a good compromise between the yield in terms of volume for multianalyses and detectable concentrations of the selected analytes.

The subjects were asked to breathe tidally through the mouthpiece for 15 min, while sitting comfortably in the workplace office where the level of total Cr was \< 0.1 μg/m^3^ (workers) or in the laboratory office (controls). They were instructed to form a complete seal around the mouthpiece with their mouths, which had to be kept dry by periodically swallowing excess saliva; they were also asked to rinse their mouths thoroughly before the maneuver and every 5 min during the test. To prevent any contamination from the skin, the subjects were asked to wash their hands before EBC and urine collection and to wear disposable latex gloves during the collecting procedures. EBC sample volume was accurately measured with a calibrated pipette, and salivary contamination was excluded by means of the colorimetric detection of alpha-amylase activity (Infinity amylase reagent; Sigma, Milan, Italy). Moreover, we measured the levels of Cr in saliva of five workers and found a maximum salivary Cr level of about 10 times higher than the corresponding EBC value, not sufficient to justify salivary contamination, given that the limit of detection (LOD) of the amylase kit was much lower (between 1/10,000 and 1/5,000) than the amylase activity measured in saliva. Finally, the EBC samples were transported in dry ice to the laboratory and stored at −80°C until analysis.

Analysis of Cr in urine and EBC.
--------------------------------

Urinary Cr (Cr-U) was measured by ETAAS and expressed as a function of creatinine. Urinary overcorrection was excluded because none of the subjects presented creatinine levels \< 30 mg/L or \> 300 mg/L. The LOD was 0.05 μg/L, and a certified standard (Fluka) was repeated every 10 samples.

The ETAAS analysis protocol was applied to the EBC samples, and the results were confirmed by inductively coupled plasma--mass spectrometry (ICP-MS) in a separate laboratory, with an interlaboratory regression coefficient of 0.95 and an average deviation between samples of about 10% (data not shown). The LOD was 0.05 μg/L.

H~2~O~2~-EBC measurements.
--------------------------

H~2~O~2~-EBC was measured as previously described ([@b8-ehp0114-000542]) using a commercial kit (Amplex Red hydrogen peroxide assay kit; Molecular Probes, Eugene, OR, USA) with an LOD of 0.01 μM. The analyses were made 2--3 days after EBC collection. Samples were stored at −80°C up to 3 days at the most ([@b19-ehp0114-000542]).

MDA-EBC measurements.
---------------------

MDA-EBC was measured by tandem liquid chromatography--mass spectrometry as previously described by [@b4-ehp0114-000542], with an LOD of 1 nM.

Statistical analysis.
---------------------

The data were analyzed using SPSS 13.0 (SPSS, Chicago, IL, USA) and PRISM 3.0 (Graphpad Software, San Diego, CA, USA). The measured parameters showed a log-normal distribution (Shapiro-Wilk test) for all the considered groups of subjects; therefore, the data were log-transformed for all of the statistical tests, and the results were expressed as the geometric mean (GM) and geometric SD (GSD). Median values and interquartile ranges are also reported. We analyzed log-transformed data using repeated-measures analysis of variance (ANOVA) followed by Tukey's multiple comparisons or a paired Student *t*-test in order to assess the differences within the workers' group at different times. One-way ANOVA, followed by Dunnett's multiple comparisons, was used to assess the differences between the workers and controls. Pearson's *r* was used to assess the correlations between variables in the log-scale. The normality is required for all parametric comparison tests, whereas for tests assessing differences between repeated measures in dependent samples, a normal distribution is required for those differences. A log-transformation of our data was necessary to satisfy both the above requirements. Moreover, such a log-transformation was necessary to limit the undue influence of the highest values on the *r*and *p*-values. A *p*-value of \< 0.05 (two-tailed) was considered significant for all of the tests.

Results
=======

Ambient Cr levels sampled during the afternoon moderately correlated with Cr-U (*r* = 0.48, *p* \< 0.05) and Cr-EBC at *T*~1~ (*r* = 0.47, *p* \< 0.05), as shown in [Figure 2](#f2-ehp0114-000542){ref-type="fig"}.

[Table 2](#t2-ehp0114-000542){ref-type="table"} shows the Cr-U and Cr-EBC levels at the different time points. Compared with the controls, the exposed workers had higher levels of both at all of the time points (except for a few Cr-EBC levels at *T*~2~) (*p* \< 0.01). Cr-U levels were higher at *T*~1~ than at *T*~0~ (*p* \< 0.05) and *T*~2~ (*p* \< 0.01), and the difference between *T*~0~ and *T*~2~ was also significant (*p* \< 0.01). Cr-EBC levels were higher at *T*~0~ and *T*~1~ than at *T*~2~ (*p* \< 0.05 and *p* \< 0.01, respectively), whereas no difference was observed between *T*~0~ and *T*~1~.

Workers' H~2~O~2~-EBC levels were higher than those of the controls at *T*~0~ (*p* \< 0.05) and *T*~1~ (*p* \< 0.01), and there was a significant difference between *T*~2~ and both *T*~0~ and *T*~1~ (*p* \< 0.05 and *p* \< 0.01, respectively); the difference between *T*~0~ and *T*~1~ was not significant ([Table 2](#t2-ehp0114-000542){ref-type="table"}).

The MDA-EBC levels of workers were not significantly higher than those of the controls at every time point, although 12 of 24 workers (whose median of Cr-EBC was 11 μg/L) presented MDA levels above the 95% confidence interval (CI) upper limit for controls (10 nM) at *T*~1~. The other workers with MDA-EBC \< 10 nM showed a median of 2.5 μg/L of Cr-EBC. The only significant difference in MDA-EBC was between *T*~1~ and *T*~2~ (*p* \< 0.01, [Table 2](#t2-ehp0114-000542){ref-type="table"}).

All nonparametric tests gave results consistent with those observed using their parametric counterpart on log-transformed values. Cr-U and Cr-EBC levels presented a weak-to-moderate correlation at all time points (*r* = 0.25, *p* \< 0.05; [Figure 3A](#f3-ehp0114-000542){ref-type="fig"}). Cr-EBC and H~2~O~2~-EBC correlated closely (*r* = 0.54, *p* \< 0.01; [Figure 3B](#f3-ehp0114-000542){ref-type="fig"}), particularly at *T*~1~ (*r* = 0.72, *p* \< 0.01; data not shown); Cr-EBC also correlated with MDA-EBC (*r* = 0.59, *p* \< 0.01; [Figure 3C](#f3-ehp0114-000542){ref-type="fig"}). H~2~O~2~ and MDA were positively correlated with each other (*r* = 0.49, *p* \< 0.01; [Figure 3D](#f3-ehp0114-000542){ref-type="fig"}).

There was also a correlation between H~2~O~2~-EBC and Cr-U levels---although it was lower than the correlation between Cr-EBC and H~2~O~2~-EBC (*r* = 0.41, *p* \< 0.01; [Figure 3E](#f3-ehp0114-000542){ref-type="fig"})---whereas the correlation between Cr-U and MDA-EBC was not significant ([Figure 3F](#f3-ehp0114-000542){ref-type="fig"}). The significance of all the correlations was confirmed by the Spearman nonparametric correlation test.

We observed no statistically significant differences in EBC-collected volumes between exposed workers (mean ± SD, 1,545 ± 255 μL at *T*~0~, 1,460 ± 270 μL at *T*~1~, and 1,570 ± 280 μL at *T*~2~) and controls (1,585 ± 240 μL). The exhaled markers did not correlate with total condensed volume, and because there were no statistical differences between the total EBC volumes at the different time points, total condensed volume was excluded from the analysis. The total expired air was not measured because, as already demonstrated by [@b17-ehp0114-000542], the total volume of expired air is highly correlated (*r* = 0.95) with the total volume of EBC.

Discussion
==========

Blood and urine are currently used for the biologic monitoring of workers exposed to Cr ([@b15-ehp0114-000542]; [@b27-ehp0114-000542], [@b26-ehp0114-000542]), and thus represent the gold standard matrices for the assessment of exposure. However, they provide little information concerning lung levels, which are not necessarily related to absorbed dose, but are certainly responsible for local inflammation on the respiratory tract. EBC analysis is a novel approach to biologic monitoring, enabling us to quantify both internal dose levels of inhaled metals and to assess epithelial-lining fluid levels of biomarkers of free radical production. The results of our study show that EBC is a suitable medium for assessing biomarkers of inflammation (i.e., oxidative stress) and that it can be used to investigate lung tissue levels and biomarkers of effect in workers exposed to Cr(VI). However, future studies are needed to look at the quantitative relationship between Cr concentration in air and EBC levels as well as the association with relevant clinical outcome to assess health effects, such as spirometry, or methacholine reactivity, and so forth.

Our study was designed to assess biologic markers at different sampling times in order to evaluate the consequences of long-term and daily lung exposure. Cr-EBC and Cr-U levels were much higher in exposed subjects than in controls at all time points. Furthermore, the two variables were only slightly positively correlated with each other, such a weak-to-moderate correlation being possibly explained by the relatively complex kinetics of Cr (long-life kinetic components inside the body, in particular after chronic exposure) and the presence of other absorption routes (e.g., dermal).

Owing to their moderate correlation with Cr levels in ambient air, both Cr-EBC and Cr-U can be considered biomarkers of exposure. However, further work is needed for a full validation of Cr-EBC as a biomarker of exposure and before this metric can be used independently to assess exposure or health risk.

Looking at the different correlations between variables, Cr-U and Cr-EBC levels seem to provide different information: there were weak or no correlations between Cr-U and biomarkers of free radical production, whereas Cr-EBC concentrations correlated with higher and significant *r-*values with both MDA and H~2~O~2~ levels in EBC, thus suggesting that they may be more representative of the lung dose responsible for local free radical production.

We assessed inflammation in the lung after Cr exposure, relying on biomarkers of oxidative stress, which may be sensitive end points for evaluating early biochemical changes in the airways. This approach will probably overcome the limitations of traditional spirometric tests, which often indicate late and frequently irreversible lung dysfunction.

Analyses of MDA and H~2~O~2~ levels in EBC have shown that they are reliable indices of airway oxidative stress ([@b9-ehp0114-000542]; [@b14-ehp0114-000542]), and they may be of some help in assessing and understanding the underlying mechanisms of metal-induced carcinogenesis. Accumulated evidence suggests that the oxidative stress caused by an imbalance of cellular free radical generation and anti-oxidative defense plays an important role in metal-induced cell responses and carcinogenesis ([@b12-ehp0114-000542]; [@b33-ehp0114-000542]). Although MDA and H~2~O~2~ levels were in the normal range after 2 days away from work, H~2~O~2~ levels increased to above-normal values after a weekly and a daily Cr exposure, whereas 50% of workers (the most exposed) showed MDA levels higher than the 95% CI upper limit of control MDA levels at the end of the work shift. However, we speculate that further influencing factors, such as individual susceptibility to Cr, may modify MDA levels. As in the case of the toxic effect of cigarette smoke on the lungs, it cannot be excluded that an intermittent and repeated inhaled Cr stimulus may also be responsible for lung damage. It is worth noting that the increased H~2~O~2~ levels observed in EBC of our workers at the end of a work day were similar to those reported by [@b16-ehp0114-000542] in chronic obstructive pulmonary disease patients during exacerbations.

Unlike their H~2~O~2~ levels, the workers' MDA-EBC levels did not increase after a day's exposure, which suggests that H~2~O~2~ may be a more sensitive marker of acute lung free radical production in more highly Cr-exposed workers. However, MDA-EBC and H~2~O~2~-EBC were positively correlated, thus confirming the idea that the biologic induction of H~2~O~2~ (a marker of inflammatory processes) may increase *in vivo* oxidative stress and lipid peroxidation products.

Because there is a good correlation between Cr levels and airway free radical production and because many studies have identified Cr(VI) as the most toxic form of Cr, we are carrying out further studies on the characterization of Cr species in EBC samples after exposure to Cr(VI).

Finally, to explain the interindividual variability (e.g., workers with an anomalous trend compared with the average), it should be considered that different jobs and tasks in a chrome-plating plant may imply exposure to different Cr species. Different physicochemical properties, in terms of valence and solubility, may imply different kinetic and dynamic properties, thus accounting for a different behavior of lining fluid (EBC) compared with urine, whose Cr content is only justified by absorption of soluble Cr(VI).

In conclusion, EBC can be considered a promising medium for investigating both long-term and recent Cr exposure at target tissue level and, together with biomarkers of free radical production, it can provide insights into the oxidative lung interactions between pulmonary tissue and pneumotoxic metals occurring in exposed workers.
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![Correlations, with linear regression lines and Pearson's *r,* between environmental airborne Cr (Cr-Air) and Cr-U (*A; r* = 0.48, *p* \< 0.05) and between Cr-Air and Cr-EBC (*B; r =* 0.47, *p* \< 0.05).](ehp0114-000542f2){#f2-ehp0114-000542}

![Correlations between variables, with linear regression lines, Pearson's *r*, and significance. (*A*) Cr-U versus Cr-EBC (*r* = 0.25, *p* \< 0.05). (*B*) Cr-EBC versus H~2~O~2~-EBC (*r* = 0.54, *p* \< 0.01). (*C*) Cr-EBC versus MDA-EBC (*r* = 0.59, *p* \< 0.01). (*D*) H~2~O~2~-EBC versus MDA-EBC (*r* = 0.49, *p* \< 0.01). (*E*) Cr-U versus H~2~O~2~ EBC (*r* = 0.41, *p* \< 0.01). (*F*) Cr-U versus MDA-EBC (*r* = 0.19, not significant).](ehp0114-000542f3){#f3-ehp0114-000542}

###### 

Demographic and clinical data of subjects participating in this study (mean ± SD).

                                                                  Controls       Chrome-plating workers
  --------------------------------------------------------------- -------------- ------------------------
  No.of subjects                                                  25             24
  Sex (male/female)                                               13/12          24/0
  Age (years)                                                     31.0 ± 6.7     37.7 ± 6.3
  Smokers/ex-/non[a](#tfn1-ehp0114-000542){ref-type="table-fn"}   0/5/20         4/2/18
  FVC (% predicted)                                               108 ± 10.4     89.8 ± 10.7
  FEV~1~ (% predicted)                                            103.7 ± 11.4   91.8 ± 12.0
  FEV~1~:FVC                                                      81.9 ± 6.3     83.1 ± 7.5

Smokers/ex-smokers/nonsmokers.

###### 

Cr-U, Cr-EBC, H~2~O~2~-EBC, and MDA-EBC levels of controls and of workers at different sampling times.

                                    Cr-U (μg/g creatinine)                                                                                                                                          Cr-EBC (μg/L)                                                                                                                                               H~2~O~2~-EBC (μM)                                                                                          MDA-EBC (nM)
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   GM (GSD)                         0.25 (2.3)                                                                                                                                                      0.28 (2.6)                                                                                                                                                  0.09 (1.6)                                                                                                 6.0 (1.5)
   Median (25th--75th percentile)   0.24 (0.09--0.45)                                                                                                                                               0.25 (0.1--0.44)                                                                                                                                            0.12 (0.05--0.2)                                                                                           6.5 (5.0--8.2)
  Workers (*T*~0~)                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   GM (GSD)                         8.2 (2.1)[\*\*](#tfn3-ehp0114-000542){ref-type="table-fn"}                                                                                                      5.3 (2.9)[\*\*](#tfn3-ehp0114-000542){ref-type="table-fn"}                                                                                                  0.36 (2.4)[\*](#tfn2-ehp0114-000542){ref-type="table-fn"}                                                  8.2 (1.5)
   Median (25th--75th percentile)   7.9 (6.2--10.8)                                                                                                                                                 7.3 (2.3--9.2)                                                                                                                                              0.44 (0.22--0.61)                                                                                          7.7 (6.6--11.5)
  Workers (*T*~1~)                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   GM (GSD)                         9.4 (2.1)[\*\*](#tfn3-ehp0114-000542){ref-type="table-fn"}^,[\#](#tfn4-ehp0114-000542){ref-type="table-fn"}^                                                    6.4 (3.4)[\*\*](#tfn3-ehp0114-000542){ref-type="table-fn"}                                                                                                  0.59 (2.0)[\*\*](#tfn3-ehp0114-000542){ref-type="table-fn"}                                                9.7 (1.7)
   Median (25th--75th percentile)   9.0 (5.6--13.4)                                                                                                                                                 7.8 (2.1--15.2)                                                                                                                                             0.69 (0.42--0.86)                                                                                          10.7 (6.9--13.4)
  Workers (*T*~2~)                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   GM (GSD)                         5.7 (2.2)[\*\*](#tfn3-ehp0114-000542){ref-type="table-fn"}^,[\#\#](#tfn5-ehp0114-000542){ref-type="table-fn"},[†](#tfn6-ehp0114-000542){ref-type="table-fn"}^   2.8 (3.2)[\*\*](#tfn3-ehp0114-000542){ref-type="table-fn"},[\#](#tfn4-ehp0114-000542){ref-type="table-fn"},[†](#tfn6-ehp0114-000542){ref-type="table-fn"}   0.19 (2.6)[\#](#tfn4-ehp0114-000542){ref-type="table-fn"},[†](#tfn6-ehp0114-000542){ref-type="table-fn"}   6.6 (1.5)[†](#tfn6-ehp0114-000542){ref-type="table-fn"}
   Median (25th--75th percentile)   5.6 (3.1--6.7)                                                                                                                                                  4.0 (1.1--6.6)                                                                                                                                              0.21 (0.09--0.35)                                                                                          6.8 (5.3--8.0)

*p* \< 0.05 and

*p* \< 0.01 compared with controls.

*p* \< 0.05 and

*p* \< 0.01 compared with *T*~0~.

*p* \< 0.01 compared with *T*~1~.
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